Recruitment of Topoisomerase I (Scl-70) to Nucleoplasmic Proteasomes in Response to Xenobiotics Suggests a Role for Altered Antigen Processing in Scleroderma

被引:18
作者
Chen, Min [1 ]
Dittmann, Assemgul [1 ]
Kuhn, Annegret [1 ]
Ruzicka, Thomas [1 ]
von Mikecz, Anna [1 ]
机构
[1] Univ Dusseldorf, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 03期
关键词
D O I
10.1002/art.20962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Scleroderma, also known as systemic sclerosis (SSc), is a chronic, life-threatening autoimmune disease characterized by a wide spectrum of manifestations and a variable evolution. The presence of particular antinuclear antibodies is often predictive of the clinical expression and prognosis of the disease, but the molecular mechanisms of the immune responses remain unclear. Recently, we have shown xenobiotic-induced recruitment of nuclear autoantigens to proteasomes in the cell nucleus in cell culture and in animal models in correlation with a unique autoantibody response. In this study, we attempted to validate our findings in patients with SSc. Methods. Using indirect immunofluorescence microscopy, run-on replication and transcription assays, immunoblotting, and proteasome activity assays, we analyzed the nuclear structure, function, and proteasomal proteolysis in HEp-2 cells treated with xenobiotics or left untreated. Blood dendritic cells (DCs) were isolated from 30 patients with SSc and age- and sex-matched control subjects to determine the subcellular localization of SSc autoantigens in relation to proteasomes. Results. Xenobiotics induced a relocation of the SSc autoantigen DNA topoisomerase I (Scl-70, topo 1) to nucleoplasmic clusters, where proteasomes degrade topo I. Colocalization of topo I with proteasomes occurred exclusively in DCs from patients with SSc who developed antibodies against this autoantigen. Neither centromeres nor other SSc autoantigens colocalized with proteasomes in DCs from patients with SSc or from control subjects. Conclusion. Alteration of nuclear structure and function by xenobiotics induces recruitment of the nuclear autoantigen topo I for proteasomal processing. This event may, in turn, lead to subsequent presentation of the resulting peptides on the cell surface and the autoimmune responses against topo I in SSc.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 37 条
[1]   Intracellular localization of proteasomal degradation of a viral antigen [J].
Antón, LC ;
Schubert, U ;
Bacík, I ;
Princiotta, MF ;
Wearsch, PA ;
Gibbs, J ;
Day, PM ;
Realini, C ;
Rechsteiner, MC ;
Bennink, JR ;
Yewdell, JW .
JOURNAL OF CELL BIOLOGY, 1999, 146 (01) :113-124
[2]   Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis [J].
CasciolaRosen, L ;
Wigley, F ;
Rosen, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (01) :71-79
[3]   DNA topoisomerases: Structure, function, and mechanism [J].
Champoux, JJ .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :369-413
[4]   Platinum-induced autoantibodies target nucleoplasmic antigens related to active transcription [J].
Chen, M ;
Hemmerich, P ;
von Mikecz, A .
IMMUNOBIOLOGY, 2002, 206 (05) :474-483
[5]   Subcellular recruitment of fibrillarin to nucleoplasmic proteasomes: Implications for processing of a nucleolar autoantigen [J].
Chen, M ;
Rockel, T ;
Steinweger, G ;
Hemmerich, P ;
Risch, J ;
von Mikecz, A .
MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (10) :3576-3587
[6]   Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin [J].
Desai, SD ;
Liu, LF ;
VazquezAbad, D ;
DArpa, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (39) :24159-24164
[7]   Topotecan and the development of scleroderma or a scleroderma-like illness [J].
Ene-Stroescu, D ;
Ellman, MH ;
Peterson, CE .
ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :844-845
[8]  
Fox Robert I., 1992, Current Opinion in Rheumatology, V4, P857
[9]   ENVIRONMENTAL SCLERODERMA [J].
HAUSTEIN, U ;
HERRMANN, K .
CLINICS IN DERMATOLOGY, 1994, 12 (03) :467-473
[10]  
Haustein UF, 1998, J RHEUMATOL, V25, P1917